Table 2.
Reported studies evaluating cisplatin or carboplatin for the treatment of patients with TNBC
| ClinicalTrials.gov identifier | Population | Therapy | Phase | Status |
|---|---|---|---|---|
| NCT01930292 | BL/claudin-low TNBC | Paclitaxel + carboplatin | I | Active, not recruiting57 |
| NCT01982448 | TNBC | Cisplatin + paclitaxel | II | Recruiting58 |
| NCT01560663 | TNBC | Docetaxel + carboplatin | I | Recruiting59 |
| NCT02393794 | mTNBC | Romidepsin + cisplatin | I/II | Recruiting60 |
| NCT01216124 | Local advanced TNBC | Docetaxel + oxaliplatin | II | Unknown61 |
| NCT01276769 | TNBC | Paclitaxel + carboplatin/epirubicin | II | Unknown62 |
| NCT01216111 | TNBC | Paclitaxel + cisplatin | III | Unknown63 |
| NCT02445391 | BL TNBC | Platinum-based chemotherapy | III | Recruiting64 |
| NCT00861705 | TNBC | Carboplatin + bevacizumab + paclitaxel + doxorubicin + cyclophosphamide | II | Active, not recruiting, has results65 |
Abbreviations: BL, basal like; TNBC, triple-negative breast cancer; mTNBC, metastatic TNBC.